Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 4Completed 4Recruiting 3Active not recruiting 3Withdrawn 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 7Peritoneal Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Appendiceal Neoplasms 3Urologic Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Recurrence 2Pseudomyxoma Peritonei 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Sarcoma 1Pleural Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Necrosis 1Mediastinal Neoplasms 1Male Urogenital Diseases 1Gastrointestinal Neoplasms 1Female Urogenital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × Mitomycin × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd.

Phase 3 Recruiting
70 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05874921 2025-02-28

uTRACT

UroGen Pharma Ltd.

Recruiting
400 enrolled
Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡